CPR-Therapeutics Announces Mike Black as Chief Strategy Officer

Mike Black

CPR Therapeutics, Inc. (CPR-T) is developing multimodal cardiopulmonary resuscitation (CPR), a more effective form of automated mechanical CPR. Sudden cardiac arrest is one of the leading causes of sudden death worldwide and there are currently no devices more effective than manual chest compressions. Intact survival after cardiac arrest is below 10% in most communities.

Dave Gaddy, CPR Therapeutic’s CEO said

“We could not be more excited to have Mike’s expertise. His background in leading the development of innovative resuscitation and EMS medical devices is uniquely strong. He was CEO of Advanced Circulatory Systems Inc. (ACSI), one of the few start-ups to innovate significantly in CPR. He went on to be Vice President of Global Customer Experience at ZOLL Medical, a leading strategic company in EMS that acquired ACSI in 2015.”

Asked to share his perspective on CPR-T, Mike Black responded “I’m looking forward to advising the CPR Therapeutics team on the development of this important suite of medical technologies. I have a long-term commitment to improving the outcome of patients suffering cardiac arrest. CPR-T’s approach is a major opportunity to advance care and have a meaningful impact on one of the leading killers worldwide.”

Dr. Paradis, CPR-T’s Founder, and Chief Medical Officer

“Mike is a great fit for helping our start-up company take on one of medicine’s most intractable problems – improving the efficacy of CPR. I genuinely believe our chances for success go up significantly having Mike in this important role.”

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.